MedTrace Logo

First-in-human Evaluation of [18F]CETO

NCT05361083 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-05-04

No results posted yet for this study

Summary

Purpose of this clinical phase 1 trial was to determine if para-chloro-2-\[18F\]fluoroethyletomidate positron emission computed tomography (\[18F\]CETO-positron emission computed tomography(PET)/computed tomography(CT)) can be used in diagnostics of adrenal tumors and if the biochemical/pharmacological states conditions in humans with various illnesses, compared to healthy humans, such as the radio tracer is suitable?

Conditions

  • Primary Aldosteronism Due to Aldosterone Producing Adenoma
  • Primary Aldosteronism Due to Nodular Hyperplasia
  • Adrenal Cushing Syndrome
  • Non-Secretory Adrenal Adenoma
  • Adrenocortical Carcinoma

Interventions

DRUG

F18CETO

Injection of F18CETO or O15water followed by PET/CT

Sponsors & Collaborators

  • Uppsala University Hospital

    collaborator OTHER

  • British Medical Research Council

    collaborator OTHER_GOV

  • Uppsala University

    lead OTHER

Principal Investigators

  • Per Hellman, Professor · Uppsala University and Uppsala University Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2021-04-01
Completion
2022-02-28

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05361083 on ClinicalTrials.gov